For research use only. Not for use in humans.
Molecular Weight(MW): 157.1
Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
2 Customer Reviews
(A) BoDV-1 infection was measured by IFA. BoDV-1 P40 was detected with a primary monoclonal antibody (red), nuclei were stained with DAPI (blue), merged image (scale bars: 50 μm). Favipiravir: T-705
Cell Physiol Biochem, 2018, 49(1):381-394. Favipiravir (T-705) purchased from Selleck.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
|Description||Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.|
Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml.  In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. 
|In vivo||In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection.  In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. |
|In vitro||DMSO||31 mg/mL (197.32 mM)|
|Ethanol||22 mg/mL warmed (140.03 mM)|
|Water||5 mg/mL warmed (31.82 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03394209||Completed||Drug: Favipiravir|Drug: Oseltamivir 75Mg Capsule||Influenza Human|Critical Illness|Influenza||Capital Medical University|Beijing Institute of Pharmacology and Toxicology|University of Oxford|Centers for Disease Control and Prevention China||February 6 2018||Phase 2|
|NCT02739477||Terminated||Drug: Favipiravir||Ebola Virus Survivor||Institut National de la Santé Et de la Recherche Médicale France||April 2016||Phase 2|
|NCT02329054||Completed||Drug: Favipiravir||Ebola Virus Disease||Institut National de la Santé Et de la Recherche Médicale France||December 2014||Phase 2|
|NCT02026349||Completed||Drug: favipiravir|Drug: Placebo||Influenza||MDVI LLC|MediVector Inc.||January 2014||Phase 3|
|NCT02008344||Completed||Drug: favipiravir|Drug: placebo||Influenza||MDVI LLC|MediVector Inc.||December 2013||Phase 3|
|NCT01728753||Completed||Drug: Placebo|Drug: Favipiravir||Influenza||MDVI LLC|United States Department of Defense||November 2012||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.